Updated information on supply of medicinal products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta)
14.08.2009
Genzyme Corporation informed the European Medicines Agency (EMEA) that the supply shortage of the medicinal products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) would be more severe than initially expected. Consequently, EMEA's Committee for Medicinal Products for Human Use (CHMP) updated its temporary treatment recommendations.
EMEA's statement and recommendations can be found at the following link: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/51296009en.pdf
